Abstract
Inhibition of the proinflammatory cytokine TNF-α has been shown to be an effective strategy for treating inflammatory dermatoses. Etanercept competitively inhibits the interaction of TNF, interrupting the proinflammatory cytokine cascade and preventing TNF mediated cellular responses. The success of etanercept in a wide range of dermatologic conditions especially in psoriasis gives a new hope in dermatological therapy field. This article reviews the pharmacokinetic properties, safety profile, administration route and efficacy in different dermatological conditions of etanercept.
Keywords: tumour necrosis factor aplha, Cytokines, TNF inhibitors, Psoriasis, Inflammatory Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Etanercept for the Treatment of Dermatological Diseases
Volume: 6 Issue: 3
Author(s): Goksun Karaman
Affiliation:
Keywords: tumour necrosis factor aplha, Cytokines, TNF inhibitors, Psoriasis, Inflammatory Diseases
Abstract: Inhibition of the proinflammatory cytokine TNF-α has been shown to be an effective strategy for treating inflammatory dermatoses. Etanercept competitively inhibits the interaction of TNF, interrupting the proinflammatory cytokine cascade and preventing TNF mediated cellular responses. The success of etanercept in a wide range of dermatologic conditions especially in psoriasis gives a new hope in dermatological therapy field. This article reviews the pharmacokinetic properties, safety profile, administration route and efficacy in different dermatological conditions of etanercept.
Export Options
About this article
Cite this article as:
Goksun Karaman , Etanercept for the Treatment of Dermatological Diseases, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2007; 6 (3) . https://dx.doi.org/10.2174/187152307781368256
DOI https://dx.doi.org/10.2174/187152307781368256 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine RANKL/RANK/OPG: Key Therapeutic Target in Bone Oncology
Current Drug Discovery Technologies Targeting Cancer with Epi-Drugs: A Precision Medicine Perspective
Current Pharmaceutical Biotechnology TNF-Related Apoptosis-Inducing Ligand (TRAIL): A Potential Candidate for Combined Treatment of Hematological Malignancies
Current Pharmaceutical Design Cancer Stem Cells in Pediatric Brain Tumors
Current Stem Cell Research & Therapy Anticancer Drug Discovery Targeting DNA Hypermethylation
Current Medicinal Chemistry Immunotherapeutic Options for Pediatric Malignancies
Current Immunology Reviews (Discontinued) Neddylation Pathway as a Novel Anti-cancer Target: Mechanistic Investigation and Therapeutic Implication
Anti-Cancer Agents in Medicinal Chemistry Mechanism and Treatment of Rituximab Resistance in Diffuse Large Bcell Lymphoma
Current Cancer Drug Targets Beyond the "Lock and Key" Paradigm: Targeting Lipid Rafts to Induce the Selective Apoptosis of Cancer Cells
Current Medicinal Chemistry Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma
Current Cancer Therapy Reviews Recognition and Function of HumanγδT Cells: Application for Tumor Immunotherapy
Current Immunology Reviews (Discontinued) Recent Concise Viewpoints of Chronic Active Epstein-Barr Virus Infection
Current Pediatric Reviews Editorial [Hot Topic: Innovative Therapeutical Approaches for Hematological Malignancies Based on Molecular Targeted Therapies (Executive Editor: Giorgio Zauli) ]
Current Pharmaceutical Design Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs
Cardiovascular & Hematological Disorders-Drug Targets The EGFR Pathway Regulates BCRP Expression in NSCLC Cells: Role of Erlotinib
Current Drug Targets Novel Strategies of Regenerative Medicine Using Chemical Compounds
Current Medicinal Chemistry Apoptosis: Potential Therapeutic Targets for New Drug Discovery
Current Medicinal Chemistry Sphingolipid Metabolism and Drug Resistance in Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design